ArticleScientific reports2025
The value of GULP1 in cancer prognosis and immunotherapy, validated from pan-cancer analysis to pancreatic cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- GULP1 Fuels Resistance to PD-1 Blockade through Lipid-Mediated Metabolic Reprogramming of Tumor-Associated Macrophages in Gastric Cancer.Cancer communications (London, England) · 2026Article
- Serum Extracellular Vesicle-Associated GULP1 Is a Key Indicator of Hepatocellular Carcinoma.Oncology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
GULP PTB domain containing engulfment adaptor 1 (GULP1) protein is involved in regulating biological processes such as endocytosis and apoptosis. The function of GULP1 in cancer, however, has been the subject of fewer studies; its importance as a potential prognostic factor in pancreatic cancer is still uncertain. Thus, the purpose of this work was to investigate GULP1's immunologic and oncogenic activities in a range of malignancies, as well as any potential relevance to pancreatic cancer. Using multiple bioinformatic databases, GULP1 expression, prognostic significance, mutation status, methylation and phosphorylation levels, biological functions, immune cell infiltration and immunotherapeutic responses and drug sensitivity were comprehensively assessed in pan-cancer and functionally validated in pancreatic cancer. The results revealed that GULP1 was differentially expressed in most tumours and correlated with poor prognostic indicators in most tumours, which may be related to the fact that GULP1 is involved in the regulation of apoptotic pathways. In addition, the differential expression of GULP1 was linked to immune cell infiltration levels, immunotherapy response, and chemotherapy resistance. GULP1 could hinder the body's ability to fight tumors and respond to immunotherapy by promoting the accumulation of immune cells and suppressing the activity of cytotoxic T lymphocytes. In pancreatic cancer, down-regulation of GULP1 expression inhibits proliferation, invasion and migration of pancreatic cancer cells. These phenotypic changes may be achieved by regulating HIPPO, mTOR, and RTK signaling pathways. Taken together, it makes sense to think that GULP1 could be a biomarker for immunotherapy and prognosis in pan- and pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.